Current Possibilities in the Correction of Hyperuricemia in Patients with Urolithiasis and Uric Acid Hypercrystallization
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to study the effectiveness of the reception and the peculiarities of the use of the drug febuxostat in the correction of the level of uric acid (UA) in the blood serum of patients with urolithiasis and uric acid (UA) hypercrystalluria compared with allopurinol.
Materials and methods. The study involved 310 patients with urolithiasis and UAH in whom hyperuricemia was detected. Patients of the 1st group (n = 124) took febuxostat, the 2nd group (n = 186) took allopurinol. Monitoring the level of UA in blood serum and urine was performed 1 time per month for the first 3 months and 1 time in 2 months for the next 10 months.
Results. Depending on the speed of reaching the target level of serum UA in the course of treatment with both drugs, three groups were identified: a – 106 (36.3%) patients with fast achievement of the target level of UA in serum (in the first 2 months); b – 100 (35.2%) patients with a significant decrease in uricemia in the first 2 months and a long time to reach the target UA values in blood serum (more than 4 months); s – 86 (29.3%) patients with severe correction of hyperuricemia (more than 6 months). The use of febuxostat makes it possible to achieve the target serum UA level faster and safer than allopurinol – after 4 months in 102 (82.3%) patients of the 1-st group compared with 61 (36.2%) patients of the 2nd group. The absolute values of the level of UA in plasma are not decisive in the choice of the initial dose of febuxostat. The criterion for the safe transfer of patients to maintenance doses of uricostatic drugs is the normalization of UA levels not only in blood serum, but also in urine. The use of febuxostat and allopurinol preparations requires an individual selection of therapeutic and maintenance doses, based on dynamic control of the level of UA in the blood serum and urine during treatment for a long period of time. A significant increase in the level of daily diuresis while taking both uricostatic drugs may indicate an improvement in renal function and also the possibility of restoring the functional state of the tubular apparatus against the background of an adequate correction of hyperuricemia, the possibility of reverse changes caused by urate nephropathy is more pronounced while taking febuxostat.
Conclusion. Febuxostat is a modern powerful uricostatic drug with a selective mechanism of action and better efficacy (93.5% in the 1st group compared to 78.1% of the patients in the 2nd group), as well as tolerance than allopurinol (side effects in 9, 6% of patients). The inclusion of febuxostat in the complex of measures for prophylactic and metaphylaxis of urolithiasis for faster and safer correction of hyperuricemia will make it possible to increase their effectiveness.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Doherty M. New insights into the epidemiology of gout. Reumatology, 2009;48:ii2-ii8.
Drixner DJ,Ho MJ.Clinikal, Humanisic, and Economik Outcomes of Gout. Am J Manag Care, 2005;11(15):S459-S464.
Bhansing KJ, at al. Gout: a clinical sindrome illustrated and discussed Neth J Med, 2010;68(9):352-359.
McGill NW.Gout and other crystal-associated arthropathies. Bailliere s Clinical Rheumatology, 2000;14(3):445-460.
Wormann RL, Shumacher HR. Monosodium Urate Crystal Deposition Arthropathy Part II: Treatmant and Long-term Managemant of the Patients With Gout. Adv Stud Med. 2005;5(4):183-194.
Shumacher HR, Wortmann RL. Monosodium Urate Crystal Deposition Arthropathy Part 1:Review of the Stage and diagnosis of Gout. Adv Stud Med, 2005;5(3):133-138.
Riches PL, at al. Recent insights into the pathogenesis of hiperuricaemia and Gout. Hum Mol Genet, 2009;18(R2):R177-R184.
Chempion EW, at al. Asimptomatic hyperuricemia. Risk and concequanes in the Normative Aging Stady. Am J Med, 1987;82:421-426.
Zhang W, at al. EULAR evidans based recommandations for gout. Part II: Management. Report of a task forse of the EULAR Standing Committee for international Clinical Stadies including Therapeutics (ESCIST) / Ann Rheum Dis, 2006;65:1312-1324.
Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: f review. Ther Clinic Risk Manag, 2008;4(6): 1209-1220.
Інструкція до медичного застосування препарату АДЕНУРІК 80/АДЕНУРІК 120мг від 18.03. 2014р. №193.
Edwards NL. Febuostat: a new treatmant for hyperuricaemsa in gout. Rheumatology, 2009;48;ii 15-ii19.
Yu K-H. Febuxostat: a novel non-purine selektive ingibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Rec Pat Inflam Allergy Drag Discov, 2007;1:69-75.
Love BL, at al. Urate-lovering therapy for gout: focus on febuxostat. Pharmacotherapy, 2010;30(6);594-608.
Okamoto K, et al. An extremely Potent ingibitor of Xanthin Oxidoreductase. Crystal structure of the enzym-ingibitor complex and mechanism of ingibition. J Biol Chem, 2003;278(3):1848-1855.
Інструкція до медичного застосування препарату Алопуринол 100 мг. Наказ № 921 від 09.08.2017 р.
Beara-Lasic L, et al. Avidences in the managment of gout: Clinical appraisal of febuxostat in the control of hyperuricemia / Int J Nephrol Renovasc Dis, 2010;3:1-10.
Shumacher HR, tt al.Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology, 2009;48:188-194.
Reinders MK, et al. Managment of hyperuricemia of gout: focus on febuxostat. Clin Interv Aging, 2010;5:7-10.
Shumacher HR, et al. Effects of Febuxostat Versus Allopurinol and Placebo in Reducing Serum Urate in Sabjects With Hyperuricemia and Gout: A 28-Week,Phase III, Randomized,Doublebind, Parallel-Group Trial. Arthritis Reum, 2008;59: 1540-1548.
Becker MA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N.Engl J Med, 2005;353:2450-2461.
Whelton A, et al, Jornal of Clinical Rheumatology 2011;17(1):7-13.
Tausche AK, et al, Rheumatol Int. 2013 Sep 12.
Zhang W et al,Ann Reum Dis 2006;65:1312-1324 (EULAR guidelines).
Ryanna D et al, Arthritis Care Res 2012;64(10):1431-46(ACR guidlines).
Maalouf N.M., Cameron M.A., Moe O.W., Sakhaee K. Novel insignts into the pathogenesis of uric acid nephrolithiasis // Opin. Nephrol. Hypertens. – 2004. – V. 13 (2). – P. 181–189.
Черненко В.В. Черненко Д.В., Желтовская Н.И., Савчук В.И. Мочекислая гиперкристаллурия и ее роль в формировании почечных конкрементов // Урология. – 2017. – № 1 (80). – С. 6–9.
Черненко Д.В., Черненко В.В., Савчук В.Й, Желтовська Н.І., Бондаренко Ю.М. Сечова кислота та її роль в патогенезі кальцій-оксалатного нефролітіазу // Здоровье мужчины. – 2018. – № 3. – С. 68–71.
Капустинська А.А. Аналіз рівня сечової кислоти у хворих на подагру в різних вікових групах // Світ медицини та біології. – 2009. – Т. 5, № 4. – С. 108–111.
Abraham A., Dzory V.E. Influence of serum uric acid level on prognosis and survival in amniotrofic lateral sclerosis: J.Neurology 2014;261:1133-8.
Bardin T. Hyperuricemia starts at 360micromoles/L(6mg/dl). Joint Bone Spine 2015;82:141-3.
Цурко В.В., Громова М.А. Общие принципы и основные рекомендации по ведению и лечению пациентов с подагрой по материалам обновленных европейских рекомендаций // Consilium Medicum. – 2017; 19: 20-24.
